U.S. FDA GRANTS LIPOGEMS® SECOND IDE APPROVAL FOR A CLINICAL TRIAL ON THE TREATMENT FOR KNEE OA

ATLANTA, Oct. 4, 2023 /PRNewswire/ -- The U. S. Food and Drug Administration (FDA) has awarded Lipogems another Investigational Device Exemption (IDE) study for the use of MicroFat for the treatment of knee osteoarthritis (OA). The second IDE Study will be conducted for the safety and...